In the February 2018 edition of the Hardman Monthly Newsletter, Nigel Hawkins addresses the issue of the UK's infrastructure expenditure, much of which is energy-related.
01 Feb 2018
The Monthly
Time Finance plc (TIME:LON), 38.7 | Abzena (ABZA:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Allergy Therapeutics plc (AGY:LON), 3.0 | Alliance Pharma plc (APH:LON), 39.2 | Arbuthnot Banking Group PLC (ARBB:LON), 1,080 | Avacta Group PLC (AVCT:LON), 49.8 | Burford Capital Limited (BUR:LON), 1,266 | Chamberlin plc (CMH:LON), 1.6 | City of London Investment Group PLC (CLIG:LON), 315 | Evgen Pharma Plc (EVG:LON), 0.9 | Gateley (Holdings) Plc (GTLY:LON), 126 | Genedrive Plc (GDR:LON), 3.4 | Murgitroyd Group (MUR:LON), 0 | Woodbois Limited (WBI:LON), 0.8 | PPHE Hotel Group Limited (PPH:LON), 1,418 | Primary Health Properties PLC (PHP:LON), 93.9 | R.E.A. Holdings plc (RE:LON), 66.2 | Redx Pharma Plc (REDX:LON), 18.5 | Scancell Holdings Plc (SCLP:LON), 10.2 | Surface Transforms PLC (SCE:LON), 9.2 | 600 Group PLC (SIXH:LON), 2.6 | Tissue Regenix Group plc (TRX:LON), 62.5 | Titon Holdings Plc (TON:LON), 75.0 | Oxford BioMedica plc (OXB:LON), 201 | ValiRx PLC (VAL:LON), 3.6
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
The Monthly
Time Finance plc (TIME:LON), 38.7 | Abzena (ABZA:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Allergy Therapeutics plc (AGY:LON), 3.0 | Alliance Pharma plc (APH:LON), 39.2 | Arbuthnot Banking Group PLC (ARBB:LON), 1,080 | Avacta Group PLC (AVCT:LON), 49.8 | Burford Capital Limited (BUR:LON), 1,266 | Chamberlin plc (CMH:LON), 1.6 | City of London Investment Group PLC (CLIG:LON), 315 | Evgen Pharma Plc (EVG:LON), 0.9 | Gateley (Holdings) Plc (GTLY:LON), 126 | Genedrive Plc (GDR:LON), 3.4 | Murgitroyd Group (MUR:LON), 0 | Woodbois Limited (WBI:LON), 0.8 | PPHE Hotel Group Limited (PPH:LON), 1,418 | Primary Health Properties PLC (PHP:LON), 93.9 | R.E.A. Holdings plc (RE:LON), 66.2 | Redx Pharma Plc (REDX:LON), 18.5 | Scancell Holdings Plc (SCLP:LON), 10.2 | Surface Transforms PLC (SCE:LON), 9.2 | 600 Group PLC (SIXH:LON), 2.6 | Tissue Regenix Group plc (TRX:LON), 62.5 | Titon Holdings Plc (TON:LON), 75.0 | Oxford BioMedica plc (OXB:LON), 201 | ValiRx PLC (VAL:LON), 3.6
- Published:
01 Feb 2018 -
Author:
Martin Hall -
Pages:
45
In the February 2018 edition of the Hardman Monthly Newsletter, Nigel Hawkins addresses the issue of the UK's infrastructure expenditure, much of which is energy-related.